Historical salary details - Dr. David Sidransky, M.D., Lead Independent Director, Champions Oncology Inc
Dr. David Sidransky, M.D. is the Lead Independent Director of Champions Oncology Inc. They also hold 3 other positions in Ascentage Pharma Group International - ADR, Orgenesis Inc and Cactus Acquisition Corp 1 Ltd - Ordinary Shares - Class A.
Dr. David Sidransky, M.D.
Lead Independent Director
$ 149.8 K
Gross Remuneration
-
Current Company
Champions Oncology Inc
| YEAR | COMPANY | POSITION | SALARY | INCREMENT |
|---|---|---|---|---|
| 2024 | Champions Oncology Inc | Lead Independent Director | 85.5 K | 3.2 % |
| 2024 | Ascentage Pharma Group International - ADR | Independent Director | 64.3 K | - |
| 2024 | Orgenesis Inc | Independent Director | - | - |
| 2024 | Cactus Acquisition Corp 1 Ltd - Ordinary Shares - Class A | Independent Director | - | - |
| 2023 | Orgenesis Inc | Independent Director | 111.3 K | - |
| 2023 | Champions Oncology Inc | Lead Independent Director | 82.9 K | 26.6 % |
| 2022 | Champions Oncology Inc | Lead Independent Director | 65.5 K | 113.4 % |
| 2022 | Cactus Acquisition Corp 1 Ltd - Ordinary Shares - Class A | Independent Director | - | - |
| 2022 | Galmed Pharmaceuticals Ltd | Lead Independent Director | - | - |
| 2022 | Orgenesis Inc | Independent Director | - | - |
| 2021 | Orgenesis Inc | Independent Director | 141.0 K | 17.0 % |
| 2021 | Champions Oncology Inc | Lead Independent Director | 30.7 K | -10.3 % |
| 2021 | Cactus Acquisition Corp 1 Ltd - Ordinary Shares - Class A | Independent Director | - | - |
| 2021 | Galmed Pharmaceuticals Ltd | Lead Independent Director | - | - |
| 2020 | Orgenesis Inc | Independent Director | 120.5 K | -33.5 % |
| 2020 | Champions Oncology Inc | Lead Independent Director | 34.2 K | 2.7 % |
| 2020 | Cactus Acquisition Corp 1 Ltd - Ordinary Shares - Class A | Independent Director | - | - |
| 2020 | Galmed Pharmaceuticals Ltd | Lead Independent Director | - | - |
| 2019 | Orgenesis Inc | Independent Director | 181.1 K | 51.3 % |
| 2019 | Champions Oncology Inc | Lead Independent Director | 33.3 K | 72.6 % |
| 2019 | Galmed Pharmaceuticals Ltd | Lead Independent Director | - | - |
| 2018 | Orgenesis Inc | Independent Director | 119.7 K | -14.9 % |
| 2018 | Champions Oncology Inc | Lead Independent Director | 19.3 K | 52.5 % |
| 2018 | Galmed Pharmaceuticals Ltd | Lead Independent Director | - | - |
| 2017 | Orgenesis Inc | Independent Director | 140.6 K | - |
| 2017 | Champions Oncology Inc | Lead Independent Director | 12.7 K | -71.8 % |
| 2017 | Galmed Pharmaceuticals Ltd | Independent Director | - | - |
| 2016 | Champions Oncology Inc | Chairman of the Board | 44.9 K | -44.7 % |
| 2016 | Galmed Pharmaceuticals Ltd | Independent Director | - | - |
| 2015 | Champions Oncology Inc | Chairman of the Board | 81.1 K | -56.3 % |
| 2015 | Akari Therapeutics Plc - ADR | - | 17.5 K | -77.0 % |
| 2015 | Akari Therapeutics Plc - ADR | Independent Director | - | - |
| 2015 | Galmed Pharmaceuticals Ltd | Independent Director | - | - |
| 2014 | Champions Oncology Inc | Chairman of the Board | 185.6 K | 2.0 % |
| 2014 | Akari Therapeutics Plc - ADR | Independent Director | 76.0 K | 334.2 % |
| 2014 | Galmed Pharmaceuticals Ltd | Independent Director | - | - |
| 2013 | Champions Oncology Inc | Chairman of the Board | 182 K | -24.8 % |
| 2013 | Akari Therapeutics Plc - ADR | Independent Director | 17.5 K | - |
| 2013 | Orgenesis Inc | Director | 12.6 K | - |
| 2012 | Champions Oncology Inc | Chairman of the Board | 242 K | 14.3 % |
| 2011 | Champions Oncology Inc | Chairman of the Board | 211.7 K | 34.0 % |
| 2010 | Champions Oncology Inc | Chairman of the Board | 158 K | 457.5 % |
| 2009 | Champions Oncology Inc | Chairman of the Board | 28.3 K | -38.2 % |
| 2008 | Champions Oncology Inc | Chairman of the Board | 45.9 K | - |
| 2007 | Champions Oncology Inc | Director | - | - |